1,2-dimyristoylphosphatidylethanolamine has been researched along with Disease Models, Animal in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adami, R; Bell, S; Brown, T; Charmley, P; Chen, F; Chen, Y; Fam, R; Farber, K; Fosnaugh, K; Harvie, P; Houston, ME; Johns, R; Kwang, E; Liu, Y; Maciagiewicz, I; Matsui, Y; McCutcheon, M; Polisky, B; Seth, S; Severson, G; So, A; Takagi, A; Templin, MV; Vaish, N; Zhu, T | 1 |
| Camilleri, JP; Williams, AS; Williams, BD | 1 |
2 other study(ies) available for 1,2-dimyristoylphosphatidylethanolamine and Disease Models, Animal
| Article | Year |
|---|---|
RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer.
Topics: Administration, Intravesical; Animals; Blotting, Western; Cell Cycle Proteins; Cell Line, Tumor; Cholesterol; Cholesterol Esters; Disease Models, Animal; Female; Gene Expression; Humans; Inhibitor of Apoptosis Proteins; Liposomes; Mice; Mice, Nude; Phosphatidylethanolamines; Polo-Like Kinase 1; Polymerase Chain Reaction; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Repressor Proteins; RNA Interference; RNA, Messenger; RNA, Small Interfering; Survivin; Urinary Bladder Neoplasms | 2011 |
Suppression of adjuvant-induced arthritis by liposomally conjugated methotrexate in the rat.
Topics: Animals; Arthritis, Infectious; Disease Models, Animal; Drug Carriers; Liposomes; Male; Methotrexate; Mycobacterium; Phosphatidylethanolamines; Rats; Rats, Inbred Lew; Severity of Illness Index | 1994 |